Market wrap

April 2021

Global markets continue rising

- Global shares rose 4.3% and 5.1% in hedged and unhedged terms, respectively. The rotation to stocks benefitting from a strong economic recovery persisted into March. Stocks with more exposure to economic growth such as the banking sector continued to rally, benefitting from the rise in growth expectations.
- Australian shares underperformed global shares rising 2.4% in March. The market was led by strength from the consumer discretionary (up 6.9%), real estate (up 6.5%) and communication services (up 5.8%) sectors. The latter benefitted from the prospects of Telstra being broken up into several smaller companies to realise the business' latent value to shareholders.
- The Australian dollar (AUD) fell 0.9% against major currencies and 1.4% against the US dollar. Investors were attracted to the relative economic strength of US amid further coronavirus cases in Europe which saw them bid up US dollars (relative to other currencies including the AUD).
- Fixed income returns were mixed as bond yields rose internationally but fell domestically. Australian bonds benefitted from the RBA commitment to keeping rates lower for a prolonged period and acceleration of its quantitative easing program.

As the pandemic lingers

Globally

- Coronavirus case growth globally has accelerated predominantly in mainland Europe and emerging market countries such as Brazil. Europe remains plagued by a slower vaccine rollout than other developed countries such as the US with concerns over the AstraZeneca vaccine and ties to rare blood clots persisting.
- The Global Composite PMI survey (a proxy for economic activity) rose to a near seven-year high in March suggesting the global economic recovery remains firmly underway.

Locally

- The RBA left interest rates unchanged in its April meeting at 0.1% and flagged leaving rates unchanged until 2024.
- The unemployment rate fell to 5.8% in February, continuing to decline from its high of 7.5% in July thanks to continued strong jobs growth with job vacancies also rising.
- Australia's vaccination program had a major setback with the effective rejection of the AstraZeneca. The Federal government has moved to secure supplies of the Pfizer vaccine with a further 20m secured (due in late 2021). Vaccine delays add to vulnerability to further coronavirus outbreaks should they occur.

Major asset class performance

Asset classes	1 month %	1 year %	5 years (p.a.) %
Australian shares	2.4%	37.5%	10.2%
Global shares (hedged)	4.3%	48.7%	13.2%
Global shares (unhedged)	5.1%	23.5%	13.7%
Global small companies (unhedged)	3.5%	45.3%	13.8%
Global emerging markets (unhedged)	0.1%	27.3%	12.3%
Global listed property (hedged)	3.9%	29.7%	3.6%
Cash	0.0%	0.1%	1.4%
Australian fixed income	0.8%	-1.8%	3.5%
International fixed income	-0.4%	1.1%	3.3%

Source: Bloomberg & IOOF, 31 March 2021

Indices used: Australian Shares: S&P/ASX 200 Accumulation Index, Global shares (hedged): MSCI World ex Australia Net Total Return (in AUD), Global shares (unhedged): MSCI World ex Australia Hedged AUD Net Total Return Index; Global small companies (unhedged): MSCI World Small Cap Net Total Return USD Index (in AUD); Global emerging markets (unhedged): MSCI Emerging Markets EM Net Total Return AUD Index; Global listed property (hedged): FTSE EPRA/NAREIT Developed Index Hedged in AUD Net Total Return; Cash: Bloomberg AusBond Bank Bill Index; Australian fixed income: Bloomberg AusBond Composite 0+ Yr Index; International fixed income: Bloomberg Barclays Global Aggregate Total Return Index Value Hedged AUD Please note: Past performance is not indicative of future performance

Currency markets

Exchange rates	At close on 31/3	1 month change %	1 year change %
USD/AUD	0.76	-1.4%	23.9%
Euro/AUD	0.65	1.5%	16.5%
Yen/AUD	84.1	2.4%	27.5%
Trade weighted index	63.9	-0.9%	16.8%

Source: Bloomberg & IOOF, 31 March 2021.

All foreign exchange rates are rounded to two decimal places where appropriate. Please note: Past performance is not indicative of future performance.

daimer: This report has been prepared by the IOOF Research team for *RI Advice Group Pty Ltd ABN 23 001 774 125 AFSL 238429. RI Advice Group Pty Ltd* is a company within the IOOF group of companies consisting of IOOF Holdings Limited ABN 49 100 103 722 and its related bodies or report is current as at the date of issue but may be superseded by future publications. The information in the report may not be reproduced, distributed or published by any recipient for any purpose without the prior written consent of *RI Advice Group Pty Ltd*. This report may be used on the distor field for this report, or may provide services to the companies referred to in this report. This report is not available for distribution outside Australia and may not be passed to not any third persons without the prior written consent of *RI Advice Group Pty Ltd*. This report is not available for distribution outside Australia and may any not be passed to not any third persons without the prior written consent of *RI Advice Group Pty*. *It Advice Group Pty* and as one (including persons from whom information in this report is sourced) may do business or sole to obasiness with companies covered in its research reports. As a result, investors should consider on any other persons makes any representativos and any or may other persons from wates any repensentativos and any and any or makes any repensentativos and associated soliciania and exclude is distribution, outside with reasonable care. Neither *RI Advice Group Pty*, and associated soliciania and exclude a disclaniania and the contents of this document (including any projections, forecasts, estimates, prospects and returns) provid solice and associated soliciania and exclude as index of the solicianian desclude and liability for any loss or damage (whether foreseeable or not foreseeable) suffect on tand biotechres. Before making any decision based on this report, sus translabel for distribution used. The formation in this report is general advice ony and does not the representatives and e

Disclaimer: This report has been prepared by the IOOF Research team for *RI* Advice *Group Pty Ltd* BM 23 001 774 125 AFSL 23459. *RI* Advice *Group Pty Ltd* is a company within the IOOF group of companies consisting of IOOF Holdings Limited ABN 49 100 103 722 and its related busies corporate. This report is corrent as at the date of lases but may be superclaided by this publications. The information in this reports control with a data for the superclaided or publications and the information in the report. Subject for may be segreduced, distributed or publication or may prove without the prior written concent of *RI* Advice *Group Pty*. *Ltd* Financial Scroup Ends (Control Pty) and the prior written concent of *RI* Advice Group Pty and associated or mitics, divice for the pty the vertices advice the endpresses and how is maintain in the reports in socient (FIG) from the weights. *RI* Advice Group Pty and associated or mitics, divice for the pty and associated or mitics, divice for the pty and associated or mitics, divice Group Pty and associated for the integration or warrange the persons may have a conflict of interest that could affect the objectivity of this report. The second the properse influence and/or pty and associated for the second second by advice Group Pty and associated for the second second by advice Group Pty on the associated second and pty and pty and associated second and the advice objectivity of this report. The second the properse individe associated second and pty the fore-second and the basis of the second second by advice Group Pty on the pty and associated for the second second second by advice Group Pty and associated second and pty the person makes any representation or warrange the delectivity of this report. Second secon